|
1
|
Smith TG, Jackson FR, Morgan CN, Carson WC, Martin BE, Gallardo-Romero N, Ellison JA, Greenberg L, Hodge T, Squiquera L, Sulley J, Olson VA, Hutson CL. Antiviral Ranpirnase TMR-001 Inhibits Rabies Virus Release and Cell-to-Cell Infection In Vitro. Viruses 2020; 12:v12020177. [PMID: 32033253 PMCID: PMC7077210 DOI: 10.3390/v12020177] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2019] [Revised: 01/30/2020] [Accepted: 02/02/2020] [Indexed: 12/25/2022] Open
Abstract
Currently, no rabies virus-specific antiviral drugs are available. Ranpirnase has strong antitumor and antiviral properties associated with its ribonuclease activity. TMR-001, a proprietary bulk drug substance solution of ranpirnase, was evaluated against rabies virus in three cell types: mouse neuroblastoma, BSR (baby hamster kidney cells), and bat primary fibroblast cells. When TMR-001 was added to cell monolayers 24 h preinfection, rabies virus release was inhibited for all cell types at three time points postinfection. TMR-001 treatment simultaneous with infection and 24 h postinfection effectively inhibited rabies virus release in the supernatant and cell-to-cell spread with 50% inhibitory concentrations of 0.2–2 nM and 20–600 nM, respectively. TMR-001 was administered at 0.1 mg/kg via intraperitoneal, intramuscular, or intravenous routes to Syrian hamsters beginning 24 h before a lethal rabies virus challenge and continuing once per day for up to 10 days. TMR-001 at this dose, formulation, and route of delivery did not prevent rabies virus transit from the periphery to the central nervous system in this model (n = 32). Further aspects of local controlled delivery of other active formulations or dose concentrations of TMR-001 or ribonuclease analogues should be investigated for this class of drugs as a rabies antiviral therapeutic.
Collapse
Affiliation(s)
- Todd G. Smith
- Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329, USA; (F.R.J.); (C.N.M.); (W.C.C.); (B.E.M.); (N.G.-R.); (J.A.E.); (L.G.); (V.A.O.); (C.L.H.)
- Correspondence: ; Tel.: +1-404-639-2282
| | - Felix R. Jackson
- Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329, USA; (F.R.J.); (C.N.M.); (W.C.C.); (B.E.M.); (N.G.-R.); (J.A.E.); (L.G.); (V.A.O.); (C.L.H.)
| | - Clint N. Morgan
- Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329, USA; (F.R.J.); (C.N.M.); (W.C.C.); (B.E.M.); (N.G.-R.); (J.A.E.); (L.G.); (V.A.O.); (C.L.H.)
| | - William C. Carson
- Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329, USA; (F.R.J.); (C.N.M.); (W.C.C.); (B.E.M.); (N.G.-R.); (J.A.E.); (L.G.); (V.A.O.); (C.L.H.)
| | - Brock E. Martin
- Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329, USA; (F.R.J.); (C.N.M.); (W.C.C.); (B.E.M.); (N.G.-R.); (J.A.E.); (L.G.); (V.A.O.); (C.L.H.)
| | - Nadia Gallardo-Romero
- Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329, USA; (F.R.J.); (C.N.M.); (W.C.C.); (B.E.M.); (N.G.-R.); (J.A.E.); (L.G.); (V.A.O.); (C.L.H.)
| | - James A. Ellison
- Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329, USA; (F.R.J.); (C.N.M.); (W.C.C.); (B.E.M.); (N.G.-R.); (J.A.E.); (L.G.); (V.A.O.); (C.L.H.)
| | - Lauren Greenberg
- Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329, USA; (F.R.J.); (C.N.M.); (W.C.C.); (B.E.M.); (N.G.-R.); (J.A.E.); (L.G.); (V.A.O.); (C.L.H.)
| | - Thomas Hodge
- Tamir Biotechnology, Inc. 12625 High Bluff Drive Suite 113, San Diego, CA 92130, USA; (T.H.); (L.S.); (J.S.)
| | - Luis Squiquera
- Tamir Biotechnology, Inc. 12625 High Bluff Drive Suite 113, San Diego, CA 92130, USA; (T.H.); (L.S.); (J.S.)
| | - Jamie Sulley
- Tamir Biotechnology, Inc. 12625 High Bluff Drive Suite 113, San Diego, CA 92130, USA; (T.H.); (L.S.); (J.S.)
| | - Victoria A. Olson
- Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329, USA; (F.R.J.); (C.N.M.); (W.C.C.); (B.E.M.); (N.G.-R.); (J.A.E.); (L.G.); (V.A.O.); (C.L.H.)
| | - Christina L. Hutson
- Poxvirus and Rabies Branch, Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Atlanta, GA 30329, USA; (F.R.J.); (C.N.M.); (W.C.C.); (B.E.M.); (N.G.-R.); (J.A.E.); (L.G.); (V.A.O.); (C.L.H.)
| |
Collapse
|